FILINGS
| SNGX 0000812796 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2010-04-28 | POS AM | POST EFFECTIVE AMENDMENT | View Document |
| 2010-04-22 | POS AM | POST EFFECTIVE AMENDMENT | View Document |
| 2010-04-20 | POS AM | POST EFFECTIVE AMENDMENT | View Document |
| 2010-04-01 | 8-K | FORM 8-K | View Document |
| 2010-03-31 | 10-K | ANNUAL REPORT | View Document |
| 2010-02-19 | SC 13G/A | View Document | |
| 2010-01-12 | SC 13G/A | View Document | |
| 2009-11-30 | SC 13G | View Document | |
| 2009-11-23 | 424B3 | PRO SUPP FOR 10Q 3Q 2009 -162375 | View Document |
| 2009-11-23 | 424B3 | PRO SUPP FOR 10Q 3Q 2009 -157322 | View Document |
| 2009-11-23 | 424B3 | PRO SUPP FOR 10Q 3Q 2009 -149239 | View Document |
| 2009-11-13 | 8-K | SOLIGENIX 8K FINANCIAL RESULTS 3Q 09 | View Document |
| 2009-11-13 | 10-Q | SOLIGENIX 10-Q 3Q 2009 | View Document |
| 2009-11-12 | 4 | FORM 4 | View Document |
| 2009-11-12 | SC 13G/A | SCHEDULE 13GA | View Document |
| 2009-10-20 | EFFECT | View Document | |
| 2009-10-20 | 424B3 | PROSPECTUS | View Document |
| 2009-10-19 | 8-K | SOLIGENIX 8K FIRST PATIENT | View Document |
| 2009-10-19 | S-1/A | AMENDED REGISTRATION STATEMENT | View Document |
| 2009-10-13 | 4 | FORM 4 | View Document |
| 2009-10-13 | 3 | FORM 3 | View Document |
| 2009-10-13 | 4 | View Document | |
| 2009-10-09 | 8-K | 8K_BOARDCHANGE | View Document |
| 2009-10-08 | 4 | View Document | |
| 2009-10-07 | S-1 | REGISTRATION STATEMENT | View Document |
| 2009-10-02 | SC 13D/A | SIGMA TAU PHARMACEUTICALS/SOLIGENIX 13D AMENDMENT NO. 1 | View Document |
| 2009-10-02 | SC 13D/A | SIGMA TAU INTERNATIONAL/SOLIGENIX 13D AMENDMENT NO. 1 | View Document |
| 2009-10-02 | SC 13D/A | SIGMA TAU FINANZIARIA/SOLIGENIX 13D AMENDMENT NO. 1 | View Document |
| 2009-10-02 | SC 13D/A | SIGMA TAU AMERICA/SOLIGENIX 13D AMENDMENT NO. 1 | View Document |
| 2009-10-02 | SC 13D/A | PAOLO CAVAZZA/SOLIGENIX 13D AMENDMENT NO. 1 | View Document |
| 2009-10-02 | SC 13D/A | CLAUDIO/SOLIGENIX 13D AMENDMENT NO. 1 | View Document |
| 2009-10-01 | 8-K | 8K_NAMECHANGE | View Document |
| 2009-09-30 | 4 | FORM 4 | View Document |
| 2009-09-29 | 8-K | CURRENT REPORT | View Document |
| 2009-09-28 | 4 | FORM 4 | View Document |
| 2009-09-28 | 4 | FORM 4 | View Document |
| 2009-09-28 | 4 | FORM 4 | View Document |
| 2009-09-22 | 8-K | DOR 8K NIH GRANT | View Document |
| 2009-08-21 | 424B3 | PROSPECTUS SUPPLEMENT FOR 10Q 2Q 2009-149239 | View Document |
| 2009-08-21 | 424B3 | PROSPECTUS SUPPLEMENT FOR 10Q 2Q 2009-157322 | View Document |
| 2009-08-14 | 10-Q | DOR 10-Q 2Q 2009 | View Document |
| 2009-08-14 | 8-K | DOR 8K FINANCIAL RESULTS 2Q 09 | View Document |
| 2009-08-11 | 4 | View Document | |
| 2009-07-09 | 4 | FORM 4 | View Document |
| 2009-07-09 | 3 | FORM 3 | View Document |
| 2009-07-09 | 4 | FORM 4 | View Document |
| 2009-07-09 | 4 | FORM 4 | View Document |
| 2009-07-09 | 4 | FORM 4 | View Document |
| 2009-07-07 | 8-K | 8K FOR CHRISTOPHER SCHNITTKER | View Document |
| 2009-07-02 | SC 13G | BIOTEX SCHEDULE 13G | View Document |
| 2009-07-02 | 3 | View Document | |
| 2009-07-02 | SC 13G | BIOTEX SCHEDULE 13G | View Document |
| 2009-05-18 | 424B3 | PROSPECTUS SUPPLEMENT 157322 1Q09 | View Document |
| 2009-05-18 | 424B3 | PROSPECTUS SUPPLEMENT FOR 10 Q 1Q 2009-149239 | View Document |
| 2009-05-15 | 8-K | DOR 8K FINANCIAL RESULTS 1Q 09 | View Document |
| 2009-05-15 | 10-Q | DOR 10Q FOR 1Q 2009 | View Document |
| 2009-05-14 | 424B3 | PROSPECTUS FUSION EQUITY | View Document |
| 2009-05-06 | EFFECT | View Document | |
| 2009-04-27 | POS AM | POS AM FUSION LINE | View Document |
| 2009-04-24 | DEFA14A | NOTICE OF INTERNET 14A | View Document |
| 2009-04-17 | EFFECT | View Document | |
| 2009-04-17 | 424B3 | PROSPECTUS FOR FEB. FINANCING 2009 | View Document |
| 2009-04-17 | DEFR14A | DEF 14A PROXY - REVISION | View Document |
| 2009-04-16 | DEF 14A | DEF 14A PROXY | View Document |
| 2009-04-15 | CORRESP | View Document | |
| 2009-04-15 | CORRESP | View Document | |
| 2009-04-14 | S-1/A | S1A FORM FOR DOR BIOPHARMA | View Document |
| 2009-04-02 | PRE 14A | PRE 14A PROXY | View Document |
| 2009-03-31 | 8-K | DOR 8K ON FINANCIAL RESULTS 2008 | View Document |
| 2009-03-30 | 10-K | DOR 10 K FOR 2008 | View Document |
| 2009-03-30 | 4 | FORM 4 | View Document |
| 2009-03-30 | 3 | FORM 3 | View Document |
| 2009-03-24 | D | View Document | |
| 2009-03-16 | 4 | FORM 4 | View Document |
| 2009-03-16 | 3 | FORM 3 | View Document |
| 2009-03-16 | 4 | FORM 4 | View Document |
| 2009-03-16 | 3 | FORM 3 | View Document |
| 2009-03-16 | 8-K | 8K FOR NEW DIRECTOR LAPOINTE AND OFFICER HAMILTON | View Document |
| 2009-03-04 | CT ORDER | View Document | |
| 2009-02-27 | D | View Document | |
| 2009-02-25 | UPLOAD | View Document | |
| 2009-02-20 | SC 13D | DOR BIOPHARMA/SIGMA TAU PHARMACEUTICALS SCHEDULE 13D - 02/11/09 | View Document |
| 2009-02-20 | SC 13D | DOR BIOPHARMA/SIGMA TAU INTERNATIONAL SCHEDULE 13D - 02/11/09 | View Document |
| 2009-02-20 | SC 13D | DOR BIOPHARMA/SIGMA TAU FINANZIARIA SCHEDULE 13D - 02/11/09 | View Document |
| 2009-02-20 | SC 13D | DOR BIOPHARAM/SIGMA TAU AMERICA SCHEDULE 13D - 02/11/09 | View Document |
| 2009-02-20 | SC 13D | DOR BIOPHARMA/PAOLO CAVAZZA SCHEDULE 13D - 02/11/09 | View Document |
| 2009-02-20 | SC 13D | DOR BIOPHARAM/CLAUDIO CAVAZZA SCHEDULE 13D - 02/11/09 | View Document |
| 2009-02-13 | S-1 | S1 FORM FOR DOR BIOPHARMA | View Document |
| 2009-02-13 | 4 | FORM 4 | View Document |
| 2009-02-13 | 4 | FORM 4 | View Document |
| 2009-02-13 | 4 | FORM 4 | View Document |
| 2009-02-03 | D | View Document | |
| 2009-01-21 | 8-K | 8K FOR PIPE OF JAN 2009 DOR | View Document |
| 2009-01-16 | 8-K | CHANGE IN AUDITORS | View Document |
| 2008-12-19 | 4 | FORM 4 | View Document |
| 2008-12-19 | 4 | FORM 4 | View Document |
| 2008-12-19 | 4 | FORM 4 | View Document |
| 2008-12-05 | D | View Document | |
| 2008-12-03 | SC 13G | SIGMA-TAU PHARMACEUTICALS/DOR BIOPHARMA - SCHEDULE 13G | View Document |
| 2008-12-03 | SC 13G | SIGMA-TAU AMERICA/DOR BIOPHARMA - SCHEDULE 13G | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
